News
News
Academy
Multimedia
Editorial Podcasts
Editorial Videos
Peer Exchange
Profiles in Medicine
Conferences
Conference Coverage
Conference Listing
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement Hubs
E-Books
Events
Sponsored Podcasts
Sponsored Videos
Webcasts
Whitepapers
Subscribe
Choose Specialty
Corporate Communications
Corporate Communications
Corporate Communications
Corporate Communications
Corporate Communications
Direct-to-Consumer
Direct-to-Consumer
Direct-to-Consumer
Direct-to-Consumer
Emerging Biopharma
Emerging Biopharma
Emerging Biopharma
IR Licensing and Partnerships
IR Licensing and Partnerships
IR Licensing and Partnerships
Market Access
Market Access
Market Access
Market Access
Medical Affairs
Medical Affairs
Medical Affairs
Medical Affairs
Operations
Operations
Operations
Operations
Operations
Patient Engagement
Patient Engagement
Regulatory
Regulatory
Regulatory
Regulatory
Sales & Marketing
Sales & Marketing
Sales & Marketing
Sales & Marketing
Sales & Marketing
Spotlight -
Latest Executive Roundtables
Asembia 2025
Sales Effectiveness
Choose Specialty
Corporate Communications
Corporate Communications
Corporate Communications
Corporate Communications
Corporate Communications
Direct-to-Consumer
Direct-to-Consumer
Direct-to-Consumer
Direct-to-Consumer
Emerging Biopharma
Emerging Biopharma
Emerging Biopharma
IR Licensing and Partnerships
IR Licensing and Partnerships
IR Licensing and Partnerships
Market Access
Market Access
Market Access
Market Access
Medical Affairs
Medical Affairs
Medical Affairs
Medical Affairs
Operations
Operations
Operations
Operations
Operations
Patient Engagement
Patient Engagement
Regulatory
Regulatory
Regulatory
Regulatory
Sales & Marketing
Sales & Marketing
Sales & Marketing
Sales & Marketing
Sales & Marketing
Spotlight
News
Academy
Multimedia
Conferences
Publications
Partner Perspectives
Resources
Subscribe
Advertisement
Brent Caslin
home
/
authors
/
brent-caslin
Brent Caslin is a senior associate with Kirkland & Ellis LLP.
Articles
New content coming soon.
Latest Updated Articles
Published: June 19th 2024
| Updated: June 24th 2024
Utilizing Biomarkers to Develop First-in-Class Antibody Drug Conjugates to Treat Advanced Solid Tumors
Published: July 25th 2025
| Updated: August 2nd 2025
Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty
Published: July 21st 2025
| Updated: August 2nd 2025
Emrelis and the Evolving Landscape of Antibody Drug Conjugates
Published: July 22nd 2025
| Updated: August 2nd 2025
Emrelis Approval Highlights FDA Confidence in ADC Oncology Treatments
Published: July 8th 2025
| Updated: August 2nd 2025
Advancing Innovation in Cancer Care: Bringing the Next Wave of Oncology Products to Market
Published: June 24th 2025
| Updated: August 2nd 2025
Developing FP&A Strategies in Today’s Environment: Q&A with Jennifer Kyle